ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

• Status: Completed
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare, when combined with chronic exercise, the effects of perindopril, losartan, and hydrochlorothiazide.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Collaborator: American Heart Association
• Treatments: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Hydrochlorothiazide; Losartan; Perindopril; Sodium Chloride Symporter Inhibitors

Criteria

Inclusion Criteria:

• Age 65 years and older

• Hypertension - untreated (Systolic Blood Pressure (SBP) ≥ 140 mm Hg or Diastolic Blood Pressure (DBP) ≥ 90 mm Hg) or treated

• Physical limitations evidenced by either:

Score ≤ 10 on the Short Physical Performance Battery OR Walking speed < 1.2 m/sec during 400 m usual-paced test

• Sedentary lifestyle, defined as <150 min/wk of moderate physical activity as assessed by CHAMPS questionnaire

• Willingness to participate in all study procedures

Exclusion Criteria:

• Failure to provide informed consent

• Inability to complete 400 m walk within 15 minutes without sitting or interpersonal assistance, as an indicator of disablement and likely inability to fully engage in the exercise intervention

• Primary indication for ACE inhibitor use, i.e. Congestive Heart Failure, CAD, diabetes

• Known hypersensitivity to ACE inhibitors

• Resistant hypertension, defined as BP > 140/90, despite the use of three or more anti-hypertensive drugs

• Office or average home SBP > 180 mm Hg or DBP > 110 mm Hg (Average home BP in any seven day period during trial)

• Primary renal disease

• Serum creatinine >2.5 mg/dL in men, or >2.0 mg/dL in women

• Serum potassium >5.0 molar equivalent/L

• Urinary protein > 1 on dipstick

• Abnormal liver enzymes (Aspartate transaminase (AST), Alanine transaminase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal)

• Severe cardiac disease, including New York Heart Association Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina

• Acute myocardial infarction identified by ECG

• Lives in a nursing home (persons living in assisted or independent housing will not be excluded)

• Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score < 24

• Unable to communicate because of severe hearing loss or speech disorder

• Severe visual impairment, which would preclude completion of the assessments and/or intervention

• Other significant co-morbid disease that would prevent participation in exercise

• Planning to move out of the area during the study time frame

• Simultaneous participation in another intervention trial